14 results found.

Melanoma (Skin) Clinical Trial using gene expression analysis; polymerase chain reaction; polymorphism analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; medical chart review

Case Comprehensive Cancer Center - Recruiting N/A or older.
- Identification of Genomic Lesions Promoting Nodal Metastasis in Malignant Melanoma.
gene expression analysis; polymerase chain reaction; polymorphism analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; medical chart review

Metastatic Melanoma, or Skin Cancer Clinical Trial using Cyclophosphamide; Fludarabine; Young TIL

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma.
Cyclophosphamide; Fludarabine; Young TIL

Brain and Central Nervous System Tumors, Intraocular Melanoma, Lu Clinical Trial using DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms.
DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Metastatic Melanoma, or Skin Cancer Clinical Trial using Cyclophosphamide; Fludarabine; Tumor Infiltrating Lymphocytes; IL-15

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma.
Cyclophosphamide; Fludarabine; Tumor Infiltrating Lymphocytes; IL-15

Metastatic Melanoma, or Skin Cancer Clinical Trial using Aldesleukin; Cyclophosphamide; Fludarabine; Young Tumor Infiltrating Lymphocytes; 1200 Gy Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI).
Aldesleukin; Cyclophosphamide; Fludarabine; Young Tumor Infiltrating Lymphocytes; 1200 Gy Irradiation

Melanoma, Skin Clinical Trial using Vitamin D3

Stanford University - Recruiting 18 years to 75 years.
- Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers.
Vitamin D3

Melanoma (Skin) Clinical Trial using MART-1; NY-ESO-1; gp100:209-217(210M); gp100:280-288(288V); Montanide ISA 51 VG; BMS-936558

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 16 years or older.
- A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma.
MART-1; NY-ESO-1; gp100:209-217(210M); gp100:280-288(288V); Montanide ISA 51 VG; BMS-936558

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), o Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer.

Melanoma (Skin) Clinical Trial using cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma.
cisplatin; sorafenib tosylate; tamoxifen citrate; adjuvant therapy

Melanoma (Skin) Clinical Trial using bevacizumab; oxaliplatin; sorafenib tosylate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma.
bevacizumab; oxaliplatin; sorafenib tosylate

Melanoma, or Skin Cancer Clinical Trial using Panobinostat; Ipilimumab

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma.
Panobinostat; Ipilimumab

Melanoma (Skin) Clinical Trial using gene expression analysis; mutation analysis; diagnostic laboratory biomarker analysis; immunohistochemistry staining method; sentinel lymph node biopsy

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Retrospective Case-Control Study of Melanoma Patients Who Have Undergone Sentinel Lymph Node Biopsy.
gene expression analysis; mutation analysis; diagnostic laboratory biomarker analysis; immunohistochemistry staining method; sentinel lymph node biopsy

Mucosal Lentiginous Melanoma, or Acral Lentiginous Malignant Mela Clinical Trial using nilotinib

Institute of Cancer Research, United Kingdom - Recruiting 18 years or older.
- A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma.
nilotinib

Malignant Skin Melanoma T0, Stage III Melanoma, Stage IV Melanoma Clinical Trial using Nilotinib

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification..
Nilotinib